Inicio / Clústeres / Medicina Innovadora / Grupos / CANNAB-BBM /
English     FacebookTwitterRSS

CANNAB-BBM

Cannabinoides

Publicaciones científicas

Publicaciones científicas

Año Total IF media Q moda Internacionalización Agregación
2017 5 3.124 Q1 80% -
2016 14 4.594 Q1 57.14% -
2015 11 13.307 Q1 45.45% -
2014 9 4.767 Q1 44.44% -
2013 9 3.993 Q1 55.56% -
2012 6 3.46 Q1 66.67% -
2011 7 5.651 Q1 71.43% -
2010 6 4.235 Q1 50% -
2009 7 4.44 Q1 28.57% -
Total 74 5.286 Q1 55.47% -

Categorías principales: Pharmacology & Pharmacy
Chemistry, Medicinal
Neurosciences


Publicaciones vinculadas con el clúster


2017


  • Synthesis of a novel CB2 cannabinoid-porphyrin conjugate based on an antitumor chromenopyrazoledione. Morales P, Moreno L, Fernández-Ruiz J, Jagerovic N. J. Porphyrins Phthalocyanines 2017; 21: 67–76
    Categoría: Chemistry, Multidisciplinary       Cuartil: 3º
    Factor de impacto: 1.087         Version PDF
  • Effects of a Sativex-like combination of phytocannabinoids on disease progression in R6/2 mice, an experimental model of Huntington’s disease. Valdeolivas S, Sagredo O, Delgado M, Pozo MA, Fernández-Ruiz Int J Mol Sci. 2017 Mar 23;18(4). pii: E684
    Categoría: Biochemistry & Molecular Biology       Cuartil: 2º
    Factor de impacto: 3.257         Version PDF
  • Altered striatal endocannabinoid signalling in a transgenic mouse model of spinocerebellar ataxia type-3. Rodríguez-Cueto C, Hernández ML, Hillard C, Maciel P, Valdeolivas S, Ramos JA, Gómez-Ruiz M, Fernández-Ruiz J. PLoS One. 2017 Apr 27;12(4):e0176521.
    Categoría: Multidisciplinary Sciences       Cuartil: 1º
    Factor de impacto: 3.057         Version PDF
  • Up-regulation of CB2 receptors in reactive astrocytes in canine degenerative myelopathy, a disease model of amyotrophic lateral sclerosis. Fernández-Trapero M, Espejo-Porras F, Rodríguez-Cueto C, Coates J, Pérez-Diaz C, de Lago E, Fernández-Ruiz J. Dis Model Mech. 2017 May 1;10(5):551-558.
    Categoría: Pathology       Cuartil: 1º
    Factor de impacto: 4.316         Version PDF
  • New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking. Ragusa G, Gómez-Cañas M, Morales P, Rodríguez-Cueto C, Pazos MR, Asproni B, Cichero E, Fossa P, Pinna GA, Jagerovic N, Fernández-Ruiz J, Murineddu G. Eur J Med Chem. 2017 Jan 4;127:398-412.
    Categoría: Chemistry, Medicinal       Cuartil: 1º
    Factor de impacto: 3.902         Version PDF

2016


  • Deiana V, Gómez-Cañas M, Pazos MR, Fernández-Ruiz J, Asproni B, Cichero E, Fossa P, Muñoz E, Deligia F, Murineddu G, García-Arencibia M, Pinna GA. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties. Eur J Med Chem. 2016 Feb 6;112:66-80
    Categoría: Chemistry, Medicinal       Cuartil: 1º
    Factor de impacto: 5.447         Version PDF
  • Del Río C, Navarrete C, Collado JA, Bellido M, Gomez-Cañas M, Pazos MR, Fernandez-Ruiz J, Pollastro F, Appendino G, Calzado MA, Cantarero I, Muñoz E. The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways. Sci Rep. 2016 Feb 18;6:21703
    Categoría: Multidisciplinary Sciences       Cuartil: 1º
    Factor de impacto: 5.578         Version PDF
  • Morales P, Whyte L, Chicharro R, Gómez-Cañas M, Pazos MR, Goya P, Irving AJ, Fernández-Ruiz J, Ross RA, Jagerovic N. Identification of novel GPR55 modulators using cell-impedance-based label-free technology. Journal of Medicinal Chemitry, 2016 Mar 10;59(5):1840-53
    Categoría: Chemistry, Medicinal       Cuartil: 1º
    Factor de impacto: 5.447         Version PDF
  • García MC, Palomo-Garo C, Gómez-Gálvez Y, Fernández-Ruiz J. Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia. Br J Pharmacol. 2016 Jul;173(13):2069-79.
    Categoría: Pharmacology & Pharmacy       Cuartil: 1º
    Factor de impacto: 4.990         Version PDF
  • Díaz-Alonso J, Paraiso-Luna J, Navarrete C, Del Río C, Cantarero I, Palomares B, Aguareles J, Fernández-Ruiz J, Bellido ML, Pollastro F, Appendino G, Calzado MA, Galve-Roperh I, Muñóz E. VCE-003.2, a novel cannabigerol derivate, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington´s disease. Sci Rep. 2016 Jul 19;6:29789.
    Categoría: Multidisciplinary Sciences       Cuartil: 1º
    Factor de impacto: 5.228         Version PDF
  • Gómez-Cañas M, Morales P, García-Toscano L, Navarrete C, Muñoz E, Jagerovic N, Fernández-Ruiz J, García-Arencibia M, Pazos MR. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile. Pharmacol Res. 2016 Aug;110:205-15
    Categoría: Pharmacology & Pharmacy       Cuartil: 1º
    Factor de impacto: 4.408         Version PDF
  • Palomo-Garo C, Gómez-Gálvez Y, García MC, Fernández-Ruiz J. Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice. Pharmacol Res. 2016 Aug;110:181-92
    Categoría: Pharmacology & Pharmacy       Cuartil: 1º
    Factor de impacto: 4.408         Version PDF
  • López-Sendón JL, García-Caldentey J, Trigo-Cubillo P, Ruiz-Romero C, García-Ribas G, Alonso-Arias A, García de Yébenes MJ, Tolón RM, Galve-Roperh I, Sagredo O, Valdeolivas S, Resel E, Ortega-Gutiérrez S, García-Bermejo ML, Fernández-Ruiz J, Guzmán M, García de Yébenes Prous J. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington´s disease. J Neurol. 2016 Jul;263(7):1390-400
    Categoría: Clinical Neurology       Cuartil: 2º
    Factor de impacto: 3.377         Version PDF
  • Morales P, Gómez-Cañas M, Navarro G, Hurst DP, Carrillo-Salinas FJ, Lagartera L, Pazos MR, Goya P, Reggio PH, Guaza C, Franco R, Fernández-Ruiz J, Nagerovic N. Chromenopyrazole, a versatile cannabinoid scaffold with in vivo activity in a model of multiple sclerosis. J Med Chem. 2016 Jul 28;59(14):6753-71. Mención honorífica. Premios Investigación Fundación Dr. Antonio Esteve.
    Categoría: Chemistry, Medicinal       Cuartil: 1º
    Factor de impacto: 5.589         Version PDF
  • Navarro G, Morales P, Rodríguez-Cueto C, Fernández-Ruiz J, Jagerovic N, Franco R. Targeting cannabinoid CB2 receptors in the Central Nervous System. Medicinal chemistry approaches with focus on neurodegenerative disorders. Front Neurosci. 2016 Sep 13;10:406
    Categoría: Neurosciences       Cuartil: 2º
    Factor de impacto: 3.398         Version PDF
  • Rodríguez-Cueto C, Hernández ML, Hillard C, Maciel P, García-García L, Valdeolivas S, Pozo MA, Ramos JA, Gómez-Ruiz M, Fernández-Ruiz J. Dysregulation of the endocannabinoid signaling system in the cerebellum and brainstem in a transgenic mouse model of spinocerebellar ataxia type-3. .Neuroscience. 2016 Dec 17;339:191-209
    Categoría: Neurosciences       Cuartil: 2º
    Factor de impacto: 3.231         Version PDF
  • Rubio M, Valdeolivas S, Piscitelli F, Verde R, Satta V, Barroso E, Montolio M, Aras LM, Di Marzo V, Sagredo O, Fernández-Ruiz J. Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome. Pharmacology Research & Perspectives 4, e00220 (2016)
    Revista pendiente de indexar.         Version PDF
  • Hernández-Folgado L, Stevenson L, Morales P, Gómez-Cañas M, Pazos MR, Cascio MG, Jagerovic N, Elguero J, Pertwee R, Goya P. Exploring the benzimidazole ring as a substitution for indole in cannabinoid allosteric modulators. Cannabis and Cannabinoid Research 1, 196-201 (2016)
    Revista pendiente de indexar.         Version PDF
  • Gómez-Gálvez Y, Palomo-Garo C, Fernández-Ruiz J, García MC. Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson´s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:200-8
    Categoría: Clinical Neurology       Cuartil: 1º
    Factor de impacto: 4.025         Version PDF

2015


  • Erdozain A, Rubio M, Valdizán EM, Pazos A, Meana JJ, Fernández-Ruiz J, Alexander S, Callado LF. The endocannabinoid system is altered in the postmortem prefrontal cortex of alcoholic subjects., Addiction Biology, 2015 Jul;20(4):773-83
    Categoría: Substance Abuse       Cuartil: 1º
    Factor de impacto: 5.914         Version PDF
  • Erdozain A, Rubio M, Fernández-Ruiz J, Meana JJ, Callado LF. Altered CB1 receptor coupling to G-proteins in the postmortem caudate nucleus adn cerebellum of alcoholic subjects. Journal of Psychopharmacology 2015 Nov;29(11):1137-45.
    Categoría: Pharmacology & Pharmacy       Cuartil: 1º
    Factor de impacto: 3.898         Version PDF
  • Ragusa G, Gómez-Cañas M, Morales P, Hurst DP, Deligia F, Pazos MR, Pinna GA, Fernández-Ruiz J, Goya P, Reggio PH, Jagerovic N, García-Arencibia M, Murineddu G. Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists. European Journal of Medicinal Chemistry 2015 Jul 15;101:651-667
    Categoría: Chemistry, Medicinal       Cuartil: 1º
    Factor de impacto: 3.432         Version PDF
  • Moreno-Martet M, Feliú A, Espejo-Porras F, Mecha M, Carrillo-Salinas FJ, Fernández-Ruiz J, Guaza C, de Lago E. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to delta-9-tetrahydrocannabinol acting through CB1 receptors. Multiple Sclerosis and Related Disorders 2015 Nov;4(6):505-11
    Categoría: Clinical Neurology       Cuartil: 4º
    Factor de impacto: 0.884         Version PDF
  • Adán de Salas-Quiroga, Javier Díaz-Alonso, Daniel García-Rincón, Floortje Remmers, David Vega, María Gómez-Cañas, Beat Lutz, Manuel Guzmán e Ismael Galve-Roperh. Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons. Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):13693-8
    Categoría: Multidisciplinary Sciences       Cuartil: 1º
    Factor de impacto: 9.674         Version PDF
  • Morales P, Blasco-Benito S, Andradas C, Gómez-Cañas M, Flores J, Goya P, Fernández-Ruiz J, Sánchez C, Jagerovic N. Selective, nontoxic CB2 cannabinoid o-quinone with in vivo activity against triple negative breast cáncer. J Med Chem. 2015 Mar 12;58(5):2256-64.
    Categoría: Chemistry, Medicinal       Cuartil: 1º
    Factor de impacto: 5.480         Version PDF
  • Valdeolivas S, Navarrete C, Cantarero I, Bellido ML, Muñoz E, Sagredo O. Neuroprotective properties of cannabigerol in Huntington´s disease. Neurotherapeutics. 2015 Jan;12(1):185-99
    Categoría: Clinical Neurology       Cuartil: 1º
    Factor de impacto: 3.883         Version PDF
  • García MC, Cinquina V, Palomo-Garo C, Rábano A, Fernández-Ruiz J. Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson´s disease. Neurosci Lett. 2015 Feb 5;587:1-4
    Categoría: Neurosciences       Cuartil: 3º
    Factor de impacto: 99.999         Version PDF
  • Espejo-Porras F, Piscitelli F, Verde R, Ramos JA, di Marzo V, de Lago E, Fernández-Ruiz J. Changes in the endocannabinoid signaling sytem in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TPP-43-related disorders. Journal of Neuroimmune Pharmacology 10(2), 233-244 (2015)
    Categoría: Pharmacology & Pharmacy       Cuartil: 2º
    Factor de impacto: 3.172         Version PDF
  • Feliú A, Moreno-Martet M, Mecha M, Carrillo-Salinas FJ, de Lago E, Fernández-Ruiz J, Guaza C. A Sativex-like combination of phytocannabinoids as disease-modifiying therapy in a viral model of multiple sclerosis. British Journal of Pharmacology 2015 Jul;172(14):3579-95
    Categoría: Pharmacology & Pharmacy       Cuartil: 1º
    Factor de impacto: 4.990         Version PDF
  • Fernández-Ruiz J, Moro MA, Martínez-Orgado J. Cannabinoids in neurodegenerative disorders and stroke/brain trauma: from preclinical models to clinical applications. Neurotherapeutics 12, 793-806 (2015)
    Categoría: Clinical Neurology       Cuartil: 1º
    Factor de impacto: 5.054         Version PDF

2014


  • Rodríguez-Cueto C, Benito C, Fernández-Ruiz J, Romero J, Hernández ML, Gómez-Ruiz M. Changes in CB1 and CB2 receptors in the postmortem cerebellum of humans affected by spinocerebellar ataxias. British Journal of Pharmacology 171, 1472-1489 (2014)
    Categoría: Pharmacology & Pharmacy       Cuartil: 1º
    Factor de impacto: 5.067         Version PDF
  • Fernández-Fernández C, Callado LF, Girón R, Sánchez E, Erdozain AM, López-Moreno JA, Morales P, Rodríguez de Fonseca F, Fernández-Ruiz J, Goya P, Meana JJ, Martín MI, Jagerovic N. Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results. Drug Design, Development & Therapy 8, 263-277 (2014)
    Categoría: Chemistry, Medicinal       Cuartil: 1º
    Factor de impacto: 3.486         Version PDF
  • González-Naranjo P, Pérez N, Campillo NE, Pérez C, Arán VJ, Girón R, Sánchez E, Martín MI, Gómez-Cañas M, García-Arencibia M, Fernández-Ruiz J, Páez JA. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer´s disease.European Journal of Medicinal Chemistry 2014;73:56-72.(2014)
    Categoría: Chemistry, Medicinal       Cuartil: 1º
    Factor de impacto: 3.499         Version PDF
  • Endocannabinoid hydrolyzing enzymes in the postmortem cerebellum of humans affected by hereditary autosomal dominat ataxias. Rodríguez-Cueto C, Benito C, Romero J, Hernández ML, Gómez-Ruiz M, Fernández-Ruiz J. Pathobiology;81:149-159 (2014)
    Categoría: Pathology       Cuartil: 3º
    Factor de impacto: 1.948         Version PDF
  • Ooms M, Rietjens R, Rangarajan J, Vunckx K, Valdeolivas S, Maes F, Himmelreich U, Fernández-Ruiz J, Bormans G, Van Laere K, Casteels C. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice. Neurobiology of Aging 35, 2858-2869 (2014)
    Categoría: Geriatrics & Gerontology       Cuartil: 1º
    Factor de impacto: 6.166         Version PDF
  • Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, DiMarzo V, Jutras-Aswad D, Notcutt W, Martinez-Orgado J, Robson P, Rohrback B, Thiele E, Whalley B, Friedman D. Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 2014 Jun;55(6):791-802.
    Categoría: Clinical Neurology       Cuartil: 1º
    Factor de impacto: 3.909         Version PDF
  • Chiarlone A, Bellocchio L, Blázquez C, Resel E, Soria-Gómez E, Cannich A, Ferrero JJ, Sagredo O, Benito C, Romero J, Sánchez-Prieto J, Lutz B, Fernández-Ruiz J, Galve-Roperh I, Guzmán M. A restricted population of CB1 cannabinoid receptors with neuroprotective activity. Proccedings of the National Academy of Sciences of the United States of America 2014 Jun 3;111(22):8257-62
    Categoría: Multidisciplinary Sciences       Cuartil: 1º
    Factor de impacto: 9.737         Version PDF
  • Moreno-Martet M, Espejo-Porras F, Fernández-Ruiz J, de Lago E. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1G93A transgenic mice and evaluation of a Sativex®-like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. CNS Neuroscience & Therapeutics 20, 809-815 (2014)
    Categoría: Neurosciences       Cuartil: 1º
    Factor de impacto: 4.443         Version PDF
  • Moreno E, Andradas C, Medrano M, Caffarel MM, Pérez-Gómez E, Blasco-Benito S, Gómez-Cañas M, Pazos MR, Irving AJ, Lluís C, Canela EI, Fernández-Ruiz J, Guzmán M, McCormick PJ, Sánchez C. Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling. Journal of Biological Chemistry 289, 21960-21972 (2014)
    Categoría: Biochemistry & Molecular Biology       Cuartil: 1º
    Factor de impacto: 4.651

2013


  • Alvarado M, Decara J, Luque MJ, Hernández-Folgado L, Gómez-Cañas M, Gómez-Ruiz M, Fernández-Ruiz J, Elguero J, Jagerovic N, Serrano A, Goya P, Rodríguez de Fonseca F. Novel antiobesity agents: synthesis and pharmacological evaluation of analogues of Rimonabant and LH21. Bioorganic Medicinal Chemistry 21, 1708-1716 (2013)
    Categoría: Chemistry, Organic       Cuartil: 2º
    Factor de impacto: 2.903         Version PDF
  • Fernández-Fernández C, Decara J, Bermúdez-Silva FJ, Sánchez E, Morales P, Gómez-Cañas M, Gómez-Ruiz M, Callado LF, Goya P, Rodríguez de Fonseca F, Martín MI, Fernández-Ruiz J, Meana JJ, Jagerovic N. Description of a bivalent cannabinoid ligand with hypophagic properties. Arch Pharm (Weinheim). 2013 Mar;346(3):171-9
    Categoría: Chemistry, Multidisciplinary       Cuartil: 2º
    Factor de impacto: 1.540         Version PDF
  • Valdeolivas S, Pazos MR, Bisogno T, Piscitelli F, Iannotti F, Allara M, Sagredo O, di Marzo V, Fernández-Ruiz J. The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: potential role of ciclooxygenase-2-dependent metabolism of 2-AG. Celll Death & Disease 4, e862
    Categoría: Cell Biology       Cuartil: 1º
    Factor de impacto: 6.044         Version PDF
  • Morales P, Vara D, Goméz-Cañas M, Zúñiga MC, Olea-Azar C, Goya P, Fernández-Ruiz J, Díaz-Laviada I, Jagerovic N. Synthetic cannabinoid quinones: preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity. European Journal of Medicinal Chemistry 70C, 111-119 (2013)
    Categoría: Chemistry, Medicinal       Cuartil: 1º
    Factor de impacto: 3.499         Version PDF
  • Espejo-Porras F, Fernández-Ruiz J, Pertwee RG, Mechoulam R, García MC. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology. 2013 Aug 4;75C:155-163
    Categoría: Pharmacology & Pharmacy       Cuartil: 1º
    Factor de impacto: 4.114         Version PDF
  • Casarejos MJ, Perucho J, Gómez A, Muñoz MP, Fernández-Estévez M, Sagredo O, Fernández-Ruiz J, Guzmán M, García de Yébenes J, Mena MA. Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis. 2013 Jan 1;35(3):525-39
    Categoría: Neurosciences       Cuartil: 2º
    Factor de impacto: 4.174         Version PDF
  • Fernández-Ruiz J, Sagredo O, Pazos MR, García C, Pertwee RG, Mechoulam R, Martínez-Orgado J. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol. 2013 Feb;75(2):323-33
    Categoría: Pharmacology & Pharmacy       Cuartil: 1º
    Factor de impacto: 3.578         Version PDF
  • Pryce G, Cabranes A, Fernández-Ruiz J, Bisogno T, Di Marzo V, Long L, Cravatt B, Giovannoni G, Baker D. Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors. Mult Scler. 19, 1896-1904
    Categoría: Clinical Neurology       Cuartil: 1º
    Factor de impacto: 4.472         Version PDF
  • Valhondo M, Marco I, Martín-Fontecha M, Vázquez-Villa H, Ramos JA, Berkels R, Lauterbach T, Benhamú B, López-Rodríguez ML. New Serotonin 5-HT1A Receptor Agonists Endowed with Antinociceptive Activity in Vivo. Journal of Medicinal Chemistry, 2013 Oct 24;56(20):7851-61
    Categoría: Chemistry, Medicinal       Cuartil: 1º
    Factor de impacto: 5.614         Version PDF

2012


  • Moreno-Martet M, Mestre L, Loría F, Guaza C, Fernández-Ruiz J, de Lago E. Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases. Neuroscience Letters 508, 67-72 (2012)
    Categoría: Neurosciences       Cuartil: 3º
    Factor de impacto: 2.026         Version PDF
  • de Lago E, Moreno-Martet M, Cabranes A, Ramos JA, Fernández- Ruiz J. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. Neuropharmacology 62, 2299-2308 (2012)
    Categoría: Pharmacology & Pharmacy       Cuartil: 1º
    Factor de impacto: 4.114         Version PDF
  • Cumella J, Hernández-Folgado L, Girón R, Sánchez E, Morales P, Hurst DP, Gómez-Cañas M, Gómez-Ruiz M, Pinto DCG, Goya P, Reggio P, Martín MI, Fernández-Ruiz J, Silva AMS, Jagerovic N. Chromenopyrazoles: non-psychoactive and selective CB1 cannabinoid agonists with peripheral antinociceptive properties. ChemMedChem 7, 452-463 (2012)
    Categoría: Chemistry, Medicinal       Cuartil: 2º
    Factor de impacto: 2.835         Version PDF
  • González-Granja A, Carrillo Salinas F, Pagani A, Gómez-Cañas M, Negui R, Navarrete C, Mecha M, Mestre L, Fiebich BL, Calzado MA, Bellido ML, Fernández-Ruiz J, Appendino G, Guaza C, Muñoz E. A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. Journal of Neuroimmune Pharmacology 7, 1002-1016 (2012)
    Categoría: Pharmacology & Pharmacy       Cuartil: 1º
    Factor de impacto: 3.802         Version PDF
  • Pazos MR, Cinquina V, Gómez A, Layunta R, Santos M, Fernández-Ruiz J, Martínez-Orgado J. Cannabidiol administration after hypoxia-ischemia to newborn rats reduces long-term brain injury and restores neurobehavioral function. Neuropharmacology 63, 776-783 (2012)
    Categoría: Pharmacology & Pharmacy       Cuartil: 1º
    Factor de impacto: 4.114         Version PDF
  • Valdeolivas S, Satta V, Pertwee RG, Fernández-Ruiz J, Sagredo O. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington´s disease: Role of CB1 and CB2 receptors. ACS Chem Neurosci. 2012 May 16;3(5):400-6
    Categoría: Chemistry, Medicinal       Cuartil: 1º
    Factor de impacto: 3.871         Version PDF

2011


  • Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernández-Ruiz J, Cuadrado A. Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental Parkinsonism. Antioxidants & Redox Signaling 14, 2347-2360 (2011).
    Categoría: Endocrinology & Metabolism       Cuartil: 1º
    Factor de impacto: 7.189         Version PDF
  • Blazquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Borner C, Benito C, Carrasco C, Diez-Zaera M, Paoletti P, Díaz-Hernández M, Ruiz C, Sendtner M, Lucas JJ, García de Yébenes J, Marsicano G, Monory K, Lutz B, Romero J, Alberch J, Ginés S, Kraus J, Fernández-Ruiz J, Galve-Roperh I, Guzmán M. Loss of striatal cannabinoid receptors is a key pathogenic factor in Huntington´s disease. Brain 134, 119-136 (2011).
    Categoría: Neurosciences       Cuartil: 1º
    Factor de impacto: 9.915         Version PDF
  • Marco I, Valhondo M, Martín-Fontecha M, Vázquez-Villa H, Del Río J, Planas A, Sagredo O, Ramos JA, Torrecillas IR, Pardo L, Frechilla D, Benhamú B, López-Rodríguez ML. New serotonin 5-HT(1A) receptor agonists with neuroprotective effect against ischemic cell damage.J Med Chem. 2011 Dec 8;54(23):7986-99.
    Categoría: Chemistry, Medicinal       Cuartil: 1º
    Factor de impacto: 5.614         Version PDF
  • García C, Palomo-Garo C, García-Arencibia M, Ramos JA, Pertwee R, Fernández-Ruiz J. Symptom-relieving and neuroprotective effects of the phytocannabinoid D9-THCV in animal models of Parkinson´s disease. British Journal of Pharmacology 163, 1495-1506 (2011).
    Categoría: Pharmacology & Pharmacy       Cuartil: 1º
    Factor de impacto: 5.067         Version PDF
  • Sagredo O, Pazos MR, Satta V, Ramos JA, Pertwee RG, Fernández-Ruiz J.Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. Journal of Neurosciences Research 89, 1509-1518 (2011).
    Categoría: Neurosciences       Cuartil: 2º
    Factor de impacto: 2.974         Version PDF
  • Rubio M, Villain H, Docagne F, Benoit DR, Ramos JA, Vivien D, Fernández-Ruiz J, Ali C. Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insults. Plos One 6, e23690 (2011)
    Categoría: Multidisciplinary Sciences       Cuartil: 1º
    Factor de impacto: 3.730
  • Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA. Prospects for cannabinoid therapies in basal ganglia disorders. British Journal of Pharmacology 163, 1365-1378 (2011)
    Categoría: Pharmacology & Pharmacy       Cuartil: 1º
    Factor de impacto: 5.067         Version PDF

2010


  • Fernández-Ruiz, J, Hernandez ML, Ramos JA. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neuroscience & Therapeutics 16, 72-91 (2010).
    Categoría: Pharmacology & Pharmacy       Cuartil: 1º
    Factor de impacto: 4.443         Version PDF
  • Fernández-Ruiz J, García C, Sagredo O, Gómez M, de Lago E. The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opinion on Therapeutic Targets 14, 387-404 (2010).
    Categoría: Pharmacology & Pharmacy       Cuartil: 1º
    Factor de impacto: 4.130         Version PDF
  • Kurz A, Double KL, Lastres-Becker I, Tozzi A, Tantucci M, Bockhart V, Bonin M, García-Arencibia M, Nuber S, Schlaudraff F, Liss B, Fernández-Ruiz J, Gerlach M, Wüllner U, Lüddens H, Calabresi P, Auburger G, Gispert S. A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice.. PLoS One 5, e11464 (2010).
    Categoría: Multidisciplinary Sciences       Cuartil: 1º
    Factor de impacto: 3.730         Version PDF
  • Innamorato NG, Jazwa A, Rojo AI, García C, Fernández-Ruiz J, Grochot-Przeczek, A, Stachurska A, Jozkowicz A, Dulak J, Cuadrado A. Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS One 5, e11838 (2010).
    Categoría: Multidisciplinary Sciences       Cuartil: 1º
    Factor de impacto: 3.730         Version PDF
  • Castillo A, Tolón MR, Fernández-Ruiz J, Romero J, Martinez-Orgado J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors. Neurobiology of Disease 37, 434-440 (2010).
    Categoría: Neurosciences       Cuartil: 1º
    Factor de impacto: 5.624         Version PDF
  • Sagar D, Jhaveri M, Richardson D, Gray R, de Lago E, Fernández-Ruiz J, Barrett D, Kendall D, Chapman V. Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain. European Journal of Neuroscience 31, 1414-1422 (2010).
    Categoría: Neurosciences       Cuartil: 2º
    Factor de impacto: 3.753         Version PDF

2009


  • Fernández-Ruiz J. The endocannabinoid system as a target for treatment of motor dysfunction. British Journal of Pharmacology 156, 1029-1040 (2009)
    Categoría: Pharmacology & Pharmacy       Cuartil: 1º
    Factor de impacto: 5.067         Version PDF
  • Arias F, Ampuero I, Sagredo O, Almodovar F, Sánchez S, Gorgojo JJ, Ramos JA. Lack of association between polymorphisms in cannabinoid receptor gene (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study. Psychiatr Genet. 2009 Dec;19(6):336.
    Categoría: Genetics & Heredity       Cuartil: 3º
    Factor de impacto: 2.365         Version PDF
  • Rubio M, de Miguel R, Fernández-Ruiz J, Gutiérrez-López D, Carai MA, Ramos JA. Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas. Drug and Alcohol Dependence 99 : 354-358 (2009).
    Categoría: Substance Abuse       Cuartil: 2º
    Factor de impacto: 3.141         Version PDF
  • Gispert S, Ricciardi F, Kurz A, Azizov M, Hoepken H, Becker D, Voos W, Leuner K, Müller W, Kudin A, Kunz W, Zimmermann A, Roeper J, Wenzel D, Jendrach M, García-Arencíbia M, Fernández-Ruiz J, Huber L, Rohrer H, Barrera M, Reichert A, Rüb U, Chen A, Nussbaum R, Auburger G. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLOS One 4, e 5777 (2009)
    Categoría: Multidisciplinary Sciences       Cuartil: 1º
    Factor de impacto: 3.730         Version PDF
  • Sagredo O, González S, Aroyo I, Pazos MR, Benito C, Lastres-Becker I, Romero JP, Tolón RM, Mechoulam R, Brouillet E, Romero J, Fernández-Ruiz J. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease. Glia 57, 1154-1167 (2009)
    Categoría: Neurosciences       Cuartil: 1º
    Factor de impacto: 5.066         Version PDF
  • Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, Sagredo O, Benito C, Romero J, Azcoitia I, Fernández-Ruiz J, Guzmán M, Galve-Roperh I. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity. Brain 132, 3152-3164 (2009).
    Categoría: Neurosciences       Cuartil: 1º
    Factor de impacto: 9.915         Version PDF
  • Orgado JM, Fernández-Ruiz J, Romero J. The endocannabinoid system in neuropathological states. International Review of Psychiatry 21, 172-180 (2009).
    Categoría: Psychiatry       Cuartil: 2º
    Factor de impacto: 1.798         Version PDF



SubirSubir

Integrantes
16


Responsable:
Javier Fernández Ruiz
MANUEL GUZMÁN PASTOR

Referencia UCM: 950344

Keywords:

Cannabinoide.

Sistema endocannabinoide.

Neuroprotección.

Enfermedades neurodegenerativas.









Ministerio de Educación, Cultura y Deporte CEI Campus de Excelencia Internacional Ministerio de Economía y Competitividad
Proyecto financiado por el Ministerio de Educación, Cultura y Deporte, y el Ministerio de Economía y Competitividad en el marco del Programa Campus de Excelencia Internacional
La navegación por este sitio web implica la aceptación del uso de cookies propias y de terceros necesarias para su correcto funcionamiento.